Board

In 2017 Prof. Dr. Kathrin Adlkofer founded Cellbox Solutions GmbH, whose operations she leads as CEO. In the same year she became a lecturer at the Institut für Entrepreneurship und Business Development of the Universität to Lübeck. Prof. Adlkofer has additionally cofounded companies such as CK Venture GmbH and Vindex GmbH. She is as well member of multiple Scientific communities.

Outside of her business ventures she is also an athletic ace, bringing home multiple Sailing World Championship medals as well as being a 2 times Olympian.

Prof. Dr. Kathrin Adlkofer is member of BIO Deutschland’s board since 2019.

Dr. Hubert Birner is Managing Partner of TVM Capital Life Science, Munich.

Dr. Birner joined TVM Capital in 2000 as investment manager. He is currently Chairman of the Board of AL-S Pharma AG, leon nanodrugs GmbH, SpePharm Holdings BV, and Smart Reporting GmbH. Over the years, he has been jointly responsible for over 50 investments in life sciences and numerous IPOs and M&A transactions.

Prior to his current position, he was Head of Business Development Europe and Marketing Director for Germany at Zeneca Agrochemicals. Dr. Birner joined Zeneca from McKinsey & Company, where he worked in the healthcare and pharmaceuticals sector. As a management consultant, he gained extensive experience in R&D management and marketing.

Norbert Hentschel is the managing director Miltenyi Biotec B.V. & Co. KG in Bergisch Gladbach since 2010. Starting originally at the company in 2001 where he oversaw area Controlling, accounting, and information technology. In the years following he started to take over more facets of the company such as the completion of acquisitions, a founding and integration of an Asian sub corporation, and helping the company adjust to massive growth.

Before this, Herr Hentschel received a Masters in economics, leading him to work in finance for E.ON AG, Düsseldorf and next at Arthur Anderson, one of the Big Five of accounting firms.

Norbert Hentschel is member of BIO Deutschland’s board since 2009, and Treasurer since 2019.

Dr. Klaus Maleck is the CFO of the ITM Group, a private radiopharmaceutical Bio-tech company founded in 2004, while also being an operating partner of Archimed SAS.

Before these current endeavors, Dr. Maleck was CEO of TETEC AG, a fully integrated development and production company for regenerative medicine, within the Aesculap/B Braun-Group.

Before Peter Mitterhofer took over as Managing Director for Germany at BioNTech in October 2024, he held management positions at various international biotech, vaccine, and pharmaceutical companies in Austria, France, Germany, Switzerland, and the US. Peter was born in Vienna, where he studied socioeconomics, an interdisciplinary field of research that examines the interactions between economic activity and social structures. Peter Mitterhofer helped build various companies, such as CMR CureDiab Metabolic Research GmbH in Düsseldorf, together with Prof. Dr. Jürgen Eckel, and is a member of the board of the AXXELIS consulting network.

Roland Sackers is Chief Financial Officer and Managing Director of QIAGEN N.V. In this role, he is responsible for the company's global financial strategy, capital market activities, and investor communications—with the aim of promoting sustainable growth and driving QIAGEN's digital transformation. In addition to finance, Mr. Sackers is also responsible for Digital Business Solutions, IT, and cybersecurity. Mr. Sackers joined QIAGEN in 1999 and was appointed Chief Financial Officer in 2004. Prior to that, he worked as an auditor at Arthur Andersen. He holds a degree in business administration (MBA) from the University of Münster. Since 2019, he has been a member of the Supervisory Board and Chairman of the Audit Committee of Evotec SE. Mr. Sackers has been a member of the BIODeutschland Executive Board since 2009 and Chairman of the Executive Board since September 2025.

Oliver Schacht joined Life Science Nord Management GmbH in Hamburg as its new Managing Director in September 2024. From 2020-2024 he was CEO of OpGen Inc. In Rockville, MD, USA and Managing Director of Curetis GmbH in Holzgerlingen. From 2011 until 2020 he was CEO of Curetis AG and Curetis N.V. From 1999 until 2011 he was cofounder and CFO of Epigenomics AG in Berlin and CEO of its US subsidiary epigenomics Inc. in Seattle, WA, USA. Oliver had started his career at Mercer Management Consulting (now Oliver Wyman) from 1995-1999.

He is a well-known expert in the biotechnology industry, having co-founded several companies and led two IPOs and three publicly listed companies on Frankfurt Stock Exchange, Euronext Amsterdam and Brussels and NASDAQ in New York, respectively. Oliver has significant experience in the development and implementation of business strategies, financing rounds, corporate finance and M&A transactions, as well as strategic alliances and collaborations.

Oliver Schacht has earned a BA (hons.) and Diploma at the European School of Business (ESB) in Reutlingen and London, as well as a Masters and PhD at the University of Cambridge in the UK. He has been a member of BIO Deutschland’s board since 2013.

Dr. Dominik Schumacher serves as Chief Executive Officer of Tubulis.

From the early founding phase on, Dominik successfully secured several prestigious start-up awards for Tubulis. In 2019, he was awarded as one of MIT’s Innovators Under 35. Dominik is also a Life Science Investor and has been actively investing in young, European biotech companies. Prior to co-founding Tubulis in 2018, Dominik worked at the Leibniz-Forschungsinstitut für Molekulare Pharmacology (FMP) and as  group leader at the Ludwig Maximillian University (LMU) in Munich.

Dominik obtained his PhD from the Humboldt University of Berlin, Germany, and studied chemistry and economics at the Heinrich Heine University in Düsseldorf.

Raffael Wohlgensinger is the founder and CEO of the German food biotech startup Formo. He holds a master's degree in strategy and international management from the University of St. Gallen. As a venture partner at Nucleus Capital, he also supports startups in the fields of synthetic biology, climate, and food resilience. Together with his team at Formo, he develops and markets bio-based milk proteins that are used to produce sustainable, delicious, and fair dairy products.